stockrowInterCure Ltd.
INCR Healthcare Drug Manufacturers Specialty & Generic
InterCure Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $78.5 million, up 18.4% from fiscal 2024.
Follow INCR
Alert me
InterCure Ltd. (INCR) EV/Sales
As of 5 November 2026, InterCure Ltd. (INCR) trades at a EV/Sales of 0.6×. Over the past ten years it has ranged from −0.2× (May 2022) to 43.4× (April 2021); the current reading is higher than 89% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.4× | (2.39%) |
| FY2024 | 0.4× | 62.47% |
| FY2023 | 0.2× | — |
| FY2022 | 0.0× | — |
| FY2021 | 3.7× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | 3.2× | 919.92% |
| Mar 2023 | 0.3× | — |
| Dec 2022 | 0.0× | — |
| Sep 2022 | −0.1× | — |
| 9 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IXHL Incannex Healthcare Inc. compare | −24.1× |
| ZYBT Zhengye Biotechnology Holding Limited compare | n/m |
| CTOR Citius Oncology, Inc. compare | n/m |
| RMTI Rockwell Medical, Inc. compare | 0.2× |
| SCYX SCYNEXIS, Inc. compare | 0.5× |
| INCR InterCure Ltd. | 0.6× |
| CPIX Cumberland Pharmaceuticals Inc. compare | 2.6× |
| CPHI China Pharma Holdings, Inc. compare | 6.2× |
| TLPH Talphera, Inc. compare | 156× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)